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Abstract: There is a growing body of evidence showing the importance of physical activity against
acute ischemic events in various organs. Ischemia/reperfusion injury (I/R) is characterized by tissue
damage as a result of restriction and subsequent restoration of blood supply to an organ. Oxidative
stress due to increased reactive oxygen species formation and/or insufficient antioxidant defense is
considered to play an important role in I/R. Physical activity not only decreases the general risk factors
for ischemia but also confers direct anti-ischemic protection via myokine production. Myokines are
skeletal muscle-derived cytokines, representing multifunctional communication channels between the
contracting skeletal muscle and other organs through an endocrine manner. In this review, we discuss
the most prominent members of the myokines (i.e., brain-derived neurotrophic factor (BDNF),
cathepsin B, decorin, fibroblast growth factors-2 and -21, follistatin, follistatin-like, insulin-like growth
factor-1; interleukin-6, interleukin-7, interleukin-15, irisin, leukemia inhibitory factor, meteorin-like,
myonectin, musclin, myostatin, and osteoglycin) with a particular interest in their potential influence
on reactive oxygen and nitrogen species formation or antioxidant capacity. A better understanding of
the mechanism of action of myokines and particularly their participation in the regulation of oxidative
stress may widen their possible therapeutic use and, thereby, may support the fight against I/R.
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1. Introduction
Tissue damage caused by ischemia/reperfusion (I/R) injury is presented in various clinical
manifestations (e.g., myocardial infarction, stroke, peripheral arterial disease, ischemic nephropathy,
etc.) and is considered to be a leading cause of death all over the world. Therefore, investigation of the
potential anti-ischemic mechanisms, compounds, and strategies to attenuate I/R injury are extensively
studied due to their great clinical importance [1,2].
I/R injury is characterized by tissue damage as a result of restriction and subsequent restoration of
blood supply to an organ. During ischemia, oxygen and nutrient deprivation leads to time-dependent
cell death [2]. The early restoration of blood flow salvages ischemic tissue and prevents complete
damage; nevertheless, the reperfusion induces additional cell death to the ischemic organ damage [2].
Accumulation of reactive oxygen species (ROS) and the consequent oxidative stress prominently
contribute to the cell death in I/R injury.
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1.1. ROS in I/R Injury
ROS are oxygen-containing reactive molecules generated in biological systems mostly by reduction
in molecular oxygen [3]. The most important representatives of ROS are superoxide anion, hydrogen
peroxide (H2O2), and hydroxyl radical. Reactive nitrogen species (RNS) contain nitrogen, and these
molecules are usually derivatives of nitric oxide (NO) or peroxynitrite (ONOO−). ROS/RNS can be
either free radicals (e.g., superoxide, hydroxyl radical, NO) or non-radical reactive species (e.g., H2O2,
ONOO−). ROS/RNS can be generated by either enzymatic or non-enzymatic processes. Enzymatic
ROS/RNS formation include the leakage of superoxide anion from mitochondrial electron transport
chain, superoxide anion production via nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases (NOX), xanthine oxidase, cyclooxygenases, uncoupled NO synthase (NOS), and production of
NO by NOS. Non-enzymatic formation of ROS/RNS includes the generation of hydroxyl radicals from
H2O2 in the Fenton or Haber–Weiss reactions or the formation of ONOO− via the rapid reaction of NO
and superoxide anion. Endogenous antioxidants are important ROS scavengers that are responsible
for maintaining ROS/RNS at normal levels. Both small molecules, such as glutathione and urate,
or enzymatic systems, including superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx),
glutathione reductase, and heme oxygenase (HO), are effective components of cellular antioxidant
mechanisms [3–5].
Oxidative stress is considered to play an important role in I/R injury, based on the findings
that ROS is elevated in I/R, scavenging ROS protects against I/R injury, and experimental generation
of ROS causes similar tissue damage to I/R (for review see [1,2,6,7]). Tissue nitro-oxidative stress
develops in I/R injury as a result of excess formation or insufficient removal of ROS and/or RNS.
Oxidative burst mainly occurs in reperfusion; nevertheless, ischemia is also accompanied by ROS
production [2,8]. Besides, ischemia-induced enzymatic alterations and metabolic consequences promote
oxidative burst at the beginning of reperfusion. Ischemia leads to diminished electron flux through
the mitochondrial respiratory chain, which, in turn, causes superoxide anion formation at complex I
and III [2], and results in the accumulation of reducing equivalents [8]. During the ischemic period,
the xanthine oxidase substrate hypoxanthine is raised, and hypoxia inhibitory factor-1α is induced,
which activates NOX [1,2,7]. Moreover, in response to hypoxia, xanthine dehydrogenase is converted to
xanthine oxidase, and the NOS cofactor tetrahydrobiopterin is oxidized to dihydrobiopterin, resulting
in the uncoupling of NOS [1,2,7]. At the beginning of reperfusion, the reintroduction of oxygen
enhances the ROS generation, called the oxygen paradox [2]. Upon reperfusion, the accumulated
reducing metabolites serve as electron donors for ROS formation in the mitochondrial respiratory
chain [8]. In the presence of oxygen, xanthine oxidase converts hypoxanthine to xanthine, accompanied
by the release of superoxide anion and hydrogen peroxide as well [1,2,7]. Uncoupled NOS and activated
NOX enzymes also generate superoxide anion during reoxygenation [1,2,7]. Finally, the imbalance
in the pro- and antioxidant systems leads to elevated ROS/RNS that may result in oxidative stress
(i.e., oxidative damage of proteins, nucleic acids, and lipids) and can trigger activation of cell death
pathways [1,2,7].
Modulation of I/R-associated oxidative stress by inhibiting ROS production and/or by enhancing
antioxidant capacity seems to be a promising strategy to attenuate I/R injury and induce tissue
protection [1,6,9]. For instance, inhibition of xanthine oxidase by allopurinol or the NOX enzyme
by diphenyliodonium may exert protection against I/R injury in different tissues [1,7]. Furthermore,
several gain or loss of function studies implicated the protective role of SOD-1 (cytosolic CuZnSOD),
SOD-2 (mitochondrial MnSOD), and SOD-3 (extracellular CuZnSOD) in I/R injury [1]. Although many
experimental studies focusing on oxidative stress modulation are promising, controversial preclinical
findings exist, and clinical translational barriers should be overcome [1,7].
1.2. Exercise-Induced Remote Organ Protection Against I/R
Enormous effort is devoted to developing approaches limiting oxidative stress and I/R-related
morbidity and mortality [9,10]. The cardiovascular beneficial effect of physical activity is well
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known [11–13]. Besides the alteration of general cardiovascular risk factors (e.g., high blood pressure
or hypercholesterolemia), exercise confers direct protection against I/R injury of a distant organ.
This protective effect may include the development of collateral arteries, alterations in circulation,
expression of endoplasmic reticulum stress proteins, and the modulation of cyclooxygenase-2 activity,
heat shock proteins, and ATP-sensitive potassium channels [14,15]. Exercise also induces antioxidant
effects [16–18] and diminishes the increased susceptibility of cardiac mitochondria to undergo
permeability transition pore opening [19]. These protective phenomena collectively are also called
exercise-induced conditioning [20]. In skeletal muscle, the active use of the contractile apparatus,
i.e., physical work or exercise training, leads to the release of a high amount of different skeletal
muscle-derived humoral factors (e.g., myokines, metabolites, non-coding regulatory RNAs, exosomes,
etc.) to regulate a variety of metabolic and cellular processes in various tissues and organs of the body,
including the adipose tissue, bone, brain (central nervous system), pancreas, liver, gastrointestinal
system, heart, and even the skeletal muscle itself. The collective term ‘myokine’ was established by
Pedersen in 2003 to be used for cytokines, which are produced and released by contracting skeletal
muscles, exerting their effects in other organs of the body [21,22] through endocrine signaling pathways.
The majority of myokines were also shown to exert protection against ischemia [20]. Moreover,
the release of several muscle-derived myokines has been observed in settings of remote ischemic
preconditioning, further emphasizing the promising beneficial role of myokines in I/R injury [23–27].
In this article, we aimed to review the impact of a set of relevant myokines [28,29] on the
modulation of ROS formation in the context of I/R in various organs. We believe that providing a recent
update and a systematic discussion of this topic may contribute to a better understanding of this field
and may potentiate further research focusing on the possible use of myokines against I/R injury [23].
2. Modulatory Role of Myokines on ROS in the Context of I/R
We have performed a preliminary search using the PubMed database, and the results are presented
in Table 1. First, we applied the name of certain myokines alone (column 2) as a search term or
extended the search with the addition of the search term ‘myokine’ (column 3). Then, myokines
(column 1) and ‘ischemia’ were searched (column 4) to check the possible involvement of the myokines
in this field. Finally, we extended this latter search with the addition of the expressions “ROS”,
“ROI”, “oxidative”, “antioxidative”, “reactive”, “nitric”, and “stress”, respectively (columns 5–11).
Based on these search results, the myokines could be classified into three categories: (i) no or very weak
documented associations between myokines and ischemia (for instance, in case of meteorin-like, musclin,
or osteoglycin, etc.); (ii) myokines showing a marked association with ischemia and ROS (e.g., fibroblast
growth factor-21 (FGF-21), irisin, leukemia inhibitory factor (LIF), etc.), and (iii) myokines with an
overwhelming number of search counts, e.g., brain-derived neurotrophic factor (BDNF), fibroblast
growth factor-2 (FGF-2), insulin-like growth factor-1 (IGF-1), and interleukin-6 (IL-6). However,
this latter group may show deceptive values since these myokines were originally identified as signaling
molecules released by non-muscular cells; for instance, IL-6 is also a well-known pro-inflammatory
cytokine secreted independently from the skeletal muscle. Therefore, the interpretation of their
ischemia/ROS connection needs further careful analysis. In the following paragraphs, we introduce
the effects of the different myokines and the current position on their possible relation to the oxidative
stress modulation in the context of I/R.
2.1. Interleukin (IL) 6
IL-6 is a multifunctional cytokine released into the blood circulation in response to physical
activity, and it is considered to be the first myokine with pleiotropic effects on different tissues [30].
IL-6 binds to the IL-6 receptor (IL-6R) and gp130 receptor complex and activates diverse signaling
pathways, including JAK/STAT3 pathway [30]. STAT3 transcription factor seems to be involved in
cardioprotection and upregulates antioxidants (e.g., SOD-2, metallothionein) [31,32]. In connection,
the antioxidant property of IL-6 has been proposed in some studies as well [33–35].
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IL-6 has been found as a mediator of exercise-induced cardioprotection against myocardial I/R
injury (Table 2) [36]. In line with these observations, few studies showed that IL-6 administration indeed
induces cardioprotection [37,38]. An IL-6 pretreatment of 10 ng/mL protected cardiomyocytes against
simulated I/R in a NO-dependent manner since the selective inhibition of NOS-2 (iNOS) abolished
the protection [38]. IL-6 pretreatment increased NOS-2 expression and did not alter the NOS-1
(nNOS) and NOS-3 (eNOS) isoforms [38]. Mitochondrial function, which correlates to ROS formation,
was also improved by IL-6 in a NO-dependent manner [38]. A loss-of-function study demonstrated
that IL-6 has a pivotal role in ischemic preconditioning via JAK-STAT signaling and upregulation of
NOS-2 and cyclooxygenase-2 (COX-2) [39]. Interestingly, McGinnis et al. showed that IL-6-mediated
exercise-induced cardioprotection did not change myocardial NOS-2 or cyclooxygenase-2, and they
suggested other possible downstream mechanisms [36].
Table 1. Demonstration of the potential correlation between myokines and reactive oxygen species
(ROS) after a Pubmed search.














BDNF 25,624 77 1092 16 0 127 101 14 41 145
CTSB 6098 6 146 2 0 13 17 5 4 13
decorin 2883 23 23 0 0 0 0 0 0 2
FGF2 17,563 7 851 4 0 69 28 0 38 51
FGF21 1914 55 30 1 0 7 2 0 1 5
follistatin 2510 42 49 0 0 4 0 0 2 7
FSTL-1 386 12 18 0 0 2 0 0 1 6
IGF-1 44,896 32 716 4 0 67 34 10 28 72
IL-6 145,377 232 5070 151 2 1204 786 120 441 897
IL-7 6671 12 23 0 0 0 0 0 0 0
IL-15 6248 95 22 0 0 1 0 0 1 5
irisin 1131 466 49 5 0 18 6 3 1 18
LIF 4576 11 69 2 0 10 12 4 2 11
METRNL 66 11 2 0 0 0 0 0 0 1
myonectin 32 25 2 0 0 0 0 0 0 0
musclin 35 8 1 0 0 1 1 0 0 1
myostatin 2997 112 22 0 0 3 1 0 1 3
osteoglycin 133 2 4 0 0 0 0 0 0 0
Column 2: total number of articles obtained after searching for certain myokines, respectively. Column 3 and 4:
we extended the search with the terms “myokine” and “ischemia”, respectively. Column 5–11: column 2 + the terms
“ischemia” and “ROS”, “ROI”, “oxidative”, “antioxidative”, “redox”, “nitric”, or “stress”, respectively. Antiox:
antioxidative; BDNF: brain-derived neurotrophic factor; CTSB: cathepsin B; FGF-2: fibroblast growth factor-2;
FGF-21: fibroblast growth factor-21; FSTL-1: follistatin-like; IGF-1: insulin-like growth factor-1; IL-6: interleukin-6;
IL-7: interleukin-7; IL-15: interleukin-15; LIF: leukemia inhibitory factor; METRLN: meteorin-like, ROI: reactive
oxygen intermediates.
It has been demonstrated that IL-6 is neuroprotective in cerebral ischemia [40–43], so it is plausible
that exercise-induced IL-6 release contributes to the protection against ischemic stroke. In vivo
administration of 50 ng IL-6 reduced cerebral infarction, restored SOD-2 expression via IL-6R-STAT3
pathway, and blocked the oxidation and dissociation of IL-6R and gp130 [40]. They suggested
that the oxidation and subsequent disruption of the IL-6 receptor contribute to I/R injury and IL-6
protects against oxidative stress by preserving IL-6 receptor complex integrity and by the upregulation
of antioxidants (e.g., SOD-2) [40]. Similar findings were obtained in oxygen–glucose deprivation
(OGD)-primary neuronal cells treated with IL-6 [40]. In neuronal stem cells, IL-6 increased the activation
of STAT3, expression of SOD-2, and decreased superoxide anion production [44]. These mechanisms
were in casual relation to the cytoprotection against OGD and in vivo ischemic stroke [44].
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Table 2. Effect of interleukin-6 (IL-6) on redox state in settings of ischemia/reperfusion injury (I/R).
Species Organ/Cell Model IL-6 Dose, Treatment Time,Route Effect of IL-6 on I/R Injury Effect of IL-6 on Redox State Ref.
control and
IL-6−/− mice heart in vivo I/R loss of function study infarct size ↓, arrhythmia ↓ NOS-2↔, COX-2↔ [36]
rat neonatal ventricularcardiomyocytes in vitro sI/R
10 ng/mL for 6 h, 24 h
before SI/R cell death ↓
NOS-2 ↑, NOS-3↔,
NOS-1↔ [38]
mice brain in vivo I/R 2 × 50 ng, 30 min before and 15min after I/R, icv. infarct size ↓ SOD-2 ↑, protein oxidation ↓ [40]
mice primary corticalneurons in vitro OGD 50 ng/mL, 30 min before OGD cell death ↓ SOD-2 ↑, protein oxidation ↓ [40]
mice neural stem cells in vitro OGD 20 ng/mL 24 h before OGD cell death ↓ SOD-2 ↑, O2•−↓ (DHE) * [44]
mice brain transplanted withneural stem cells (NSC) in vivo I/R
NSC cells treated with 20
ng/mL 24 h before
transplantation
infarct size ↓, behavior ↑ O2•−↓ (DHE) * [44]
rat liver in vivo I/R 2 × 10–500 µg/kg, 12 h and 6 hbefore I/R, ip. cell death ↓
HSP70 ↑,
unfolded protein response ↓ [45]
rat primary culturedhepatocytes in vitro sI/R 10 ng/mL 24–72 h before H/R cell death ↓ SOD-2 ↑ [46]
Zucker rat fatty liver in vivo I/R 500 µg/kg, 12 h or 24 hbefore I/R, ip. cell death ↓
MDA ↓, GSH ↑,
HO-1 ↓, NF-kB↓ [47]
COX-2: cyclooxygenase-2, DHE: Dihydroethidium assay, GSH: glutathione, HO: heme oxygenase, HSP70: heat shock protein 70, ip.: intraperitoneally, icv.: intracerebroventricularly,
MDA: malondialdehyde, SOD-2: MnSOD, NF-kB: nuclear factor kappa-light-chain-enhancer of activated B cells, NOS-1, NOS-2, and NOS-3: neuronal/inducible/endothelial nitric oxide
synthase, O2•−: superoxide anion, OGD: oxygen-glucose deprivation, sI/R: simulated ischemia/reperfusion, SOD: superoxide dismutase, ↑ and ↓indicate increase and decrease, respectively;
↔ indicates no changes; * indicates the detection method.
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IL-6 also seemed to participate in the protection against I/R injury in the liver and be associated
with ROS modulation [45–47]. IL-6 treatment decreased oxidative stress–responsive HO-1 and
NF-kappaB, accumulation of MDA, and increased GSH content in fatty liver subjected to I/R [47].
MnSOD (SOD-2) was increased in response to IL-6 in hypoxia/reoxygenation-exposed hepatocytes
via STAT3 pathways [46]. Interestingly, Tiberio et al. suggested that Hsp70 expression may play an
important role in the IL-6-induced hepatoprotection [45], partly because Hsp70 increases antioxidant
GSH content by the modulation of glutathione-related enzymes [48].
2.2. Irisin
Irisin, the derivative of the fibronectin type III domain-containing protein 5 (FNDC5), was first
described in 2013 [49]. Irisin is capable of inducing changes in adipose tissue [50,51] by increasing the
expression of uncoupling protein-1 (UCP-1), thereby leading to the conversion of white adipose tissue
to brown adipose tissue (by a process termed browning) and resulting in the formation of the beige
adipose tissue. Irisin also increases thermogenesis, metabolism of lipids and glucose, and reduces
adipogenesis [52,53]. The intracellular signaling pathway of browning is based on the phosphorylation
of mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinases (ERKs)
and p38 protein [50,54].
The potential protective effect of irisin in ischemia (and reperfusion), particularly in the
myocardium via ROS formation, has been presented by a few papers (Table 3). Wang and colleagues
found that exogenous irisin administration (100µg/kg intraperitoneally) plays a pivotal role in protecting
the heart against I/R injury by increasing SOD-1 levels in C57/BL6 mice [55]. Similarly, another study
showed that 1 µg/kg intravenous administration of exogenous irisin produced dose-dependent
protection against I/R-induced injury to the heart, reduced total ROS production, and simultaneously
increased SOD activity [56]. They also found that in the presence of heat-denatured irisin, the protective
effects on cardiac I/R injury were lost. In another paper, irisin treatment reduced the levels of ROS and
increased the levels of components of the antioxidative system, including glutathione, SOD, and GPx via
the dynamin-like GTPase optic atrophy 1 protein [57]. Administration of exogenous irisin also conferred
protection against I/R-induced injury and oxidative stress in the lung [58]. Irisine at 12.5–50 nmol/L
concentration mitigated oxygen–glucose deprivation (OGD)-induced neuronal injury and reversed
OGD-induced oxidative stress in neuronal cells [59], and in a similar model, it suppressed the levels
of nitrotyrosine, superoxide anion, and 4-hydroxynonenal (4-HNE) in peri-infarct brain tissues [60].
Intravenous irisin administration reduced malondialdehyde and myeloperoxidase levels but increased
SOD and GPx activities in a mouse model of intestinal I/R injury [61] and significantly decreased the
ROS accumulation. It decreased the levels of MDA, XO, and 4-HNT, while it increased the levels of SOD
and GPx in intestinal tissues after gut I/R which was neutralized by irisin antibody [62]. Exogenous
irisin significantly decreased oxidative stress in hepatic I/R [63–65]. Irisin given intraperitoneally at
250µg/kg concentration reduced ER stress and oxidative stress after renal I/R, which was associated
with the upregulation of GPx-4. TRSL3 (a GPx4 inhibitor) reduced the expression of GPx4 and
abolished the protective effects of irisin in I/R-induced acute kidney injury, suggesting that GPx4 is a
vital component in irisin’s protective effect after renal I/R. [66]. Irisin administration at a concentration
of 100µg/kg increased SOD and reduced MDA levels relative to those mice in the renal I/R group,
indicating that irisin has a protective effect on the kidney by inhibiting oxidative stress in I/R injury [67].
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Table 3. Effect of Irisin on redox state in settings of I/R.
Species Organ/Cell Model Irisin Dose, TreatmentTime, Route Effect of Irisin on I/R Injury
Effect of Irisin on Redox
State Ref.
mice heart ex vivo I/R 100 µg/kg, 30 min before I/R,ip. infarct size ↓, function ↑ SOD-1 ↑ [55]
rat heart in vivo I/R 1 µg/kg immediately beforereperfusion, iv. infarct size ↓, function ↑
total SOD ↑,
SOD-1↔, SOD-2 ↑ [56]
rat H9c2 cardiomyoblasts in vitro A/R 100 ng/mL, duringreoxygenation cell death ↓ ROS ↓ (DCFH-DA/DHE) * [56]
N.A. primarycardiomyocytes in vitro H/R N.A. cell death ↓
ROS ↓ (CM-H2-DCFDA) *,
GSH ↑,
total SOD ↑, GPx ↑
[57]
control and
UCP-2−/− mice lung in vivo I/R
1 µg/kg immediately after
ischemia, iv. function ↑, edema ↓ ROS ↓ (DHE) *, UCP-2 ↑ [58]
human A549 lung epithelial cell in vitro A/R 0.1 µg/mL immediately afteranoxia apoptosis ↓ O2
•−
↓ (MitoSOX) * [58]
rat PC12 neuronal cells in vitro OGD 12.5–50 nmol/L before OGD cell death ↓, apoptosis ↓ ROS ↓ (ROS assay) *, MDA ↓,total SOD ↑ [59]
mice brain in vivo I/R 0.2 µg/g, 30 min afterischemia, iv. infarct size ↓, inflammation ↓
O2•− ↓ (superoxide assay) *,
MDA↔,
4-HNE ↓, nitrotyrosine ↓
[60]
mice intestine in vivo I/R 10ng/g or 100ng/g, 30 minbefore I/R, iv. morphology ↑, inflammation ↓
MDA ↓, MPO ↓,
total SOD ↑, GPx ↑ [61]
rat IEC-6 intestinalepithelial cells in vitro H/R 10 ng/mL 24 h before hypoxia cell death ↓ MDA ↓, total SOD ↑, GPx ↑ [61]
mice intestine in vivo I/R 250µg/kg, beginning ofreperfusion, iv. gut barrier function ↑
4-HNE ↓, MDA ↓,
total SOD ↑, GPx ↑, XOR ↓ [62]
human Caco-2 colon cells in vitro H/R 10 nmol/L, beginning ofreoxygenation cell death ↓ ROS ↓ (DHE) * [62]
rat liver in vivo I/R 250µg/kg, beginning ofreperfusion, iv. cell death ↓, inflammation ↓ MDA ↓, total SOD ↑, GPx ↑ [63]
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Table 3. Cont.
Species Organ/Cell Model Irisin Dose, TreatmentTime, Route Effect of Irisin on I/R Injury
Effect of Irisin on Redox
State Ref.
human HL-7702 hepatocytes in vitro H/R 100 ng/mL, duringreoxygenation apoptosis ↓ ROS ↓ (DHE) *, UCP-2 ↑ [63]
rat liver in vivo I/R 250µg/kg, beginning ofreperfusion, iv. cell death ↓, inflammation ↓ MDA ↓, total SOD ↑, GPx ↑ [64]
mice liver in vivo I/R 250µg/kg, beginning ofreperfusion, ip. cell death ↓ ROS ↓ (DHE) *, GPx ↑ [65]
mice kidney in vivo I/R 250µg/kg, beginning ofreperfusion, ip.
cell death ↓, function ↑,
inflammation ↓
ROS ↓ (DHE) *, total SOD ↑,
GPx ↑ [66]
mice kidney in vivo I/R 10, 100, and 200µg/kg/day for14 days before I/R, ip. tubular injury ↓, function ↑
MDA ↓, UCP-2 ↑, MPO ↓,
total SOD ↑ [67]
4-HNE: 4-hydroxynonenal, A/R: anoxia/reoxygenation, DHE: Dihydroethidium assay, GPx: glutathione peroxidase, H/R: hypoxia/reoxygenation, ip.: intraperitoneally, iv.: intravenously,
MDA: malondialdehyde, SOD-1: CuZnSOD, SOD-2: MnSOD, MPO: myeloperoxidase, N.A.: not available, O2•−: superoxide anion, OGD: oxygen–glucose deprivation, ROS: reactive
oxygen species, SOD: superoxide dismutase, UCP-2: mitochondrial uncoupling protein 2, XOR: xanthine oxidoreductase, ↑ and ↓indicate increase and decrease, respectively;↔ indicates
no changes; * indicates detection method.
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2.3. Brain-Derived Neurotrophic Factor (BDNF)
It is well accepted that muscle contraction-induced myokine release, particularly BDNF,
has neurotrophic and neuroprotective effects [68]. The neurotrophic factor BDNF is an important
regulator for the development of brain circuits, neuronal development, synaptic and neuronal
network plasticity, as well as for neuroregeneration and neuroprotection and modulation of synaptic
activity [69]. Independently of the neuronal properties, neurotrophins exert unique cardiovascular
activities. The heart is innervated by sensory, sympathetic, and parasympathetic neurons, which require
neurotrophins during early development and in the establishment of mature properties, contributing
to the maintenance of cardiovascular homeostasis. The identification of molecular mechanisms that
are regulated by neurotrophins and involved in the crosstalk between cardiac sympathetic nerves,
cardiomyocytes, cardiac fibroblasts, and vascular cells has a fundamental importance in normal heart
function and direct the response of the cardiovascular system to acute and chronic injury [70,71]. It is
well accepted that BDNF acts on its downstream target receptor, the tropomyosin receptor kinase B,
thereby activating the (BDNF)/TrkB pathway.
Based on a Pubmed search, a high number of hits were found for the term ‘BDNF’ and ‘ischemia’
(1092). Therefore, we expected a lot of new or possible links between BDNF and ROS. However,
only a few articles were found showing direct evidence between BDNF and ROS-induced regulation of
ischemia (Table 4). González-Rodríguez and Ugidos investigated exogenous BDNF administration in
ex vivo rat brain slices subjected to oxygen and glucose deprivation (OGD) models. They showed that
BDNF in a concentration of 50 ng/mL given into the medium was capable of conferring neuroprotective
effect and preventing oxidative stress characterized by decreased ROS production (tissue ROS
production, NADPH oxidase activity, and lipid peroxidation) [72]. The direct effect of BDNF on ROS
was also shown in PC12h cells. BDNF did not seem to change the total amount of ROS in the cells
treated with xanthine and xanthine oxidase but increased superoxide anion and decreased H2O2 levels
in neurons of the central nervous system, suggesting that reducing the conversion from superoxide
anion to H2O2 is also critical for the protection by BDNF [73]. In contrast to these findings, others found
that the expression and activation of NADPH oxidase were increased after a 2-day exposure to BDNF.
In primary cortical cell cultures, BDNF produced oxidative stress in cortical neurons through NADPH
oxidase-mediated production of superoxide anion, and BDNF induced expression and activation of
NADPH oxidase, which caused oxidative neuronal necrosis [74]. A similar finding was published in
human vascular endothelium: BDNF induced NOX-derived ROS generation through activation of p47
phox in a TrkB receptor-dependent manner, which led to the promotion of angiogenic tube formation
possibly via Akt activation [75].
The potential protective role of BDNF against ischemia was proved by the BDNF mimetic
7,8-dihydroxyflavone (7,8-DHF). Intraperitoneal administration of 5 mg/kg 7,8-DHF two days after
ischemia for four weeks attenuated cardiac dysfunction and cardiomyocyte abnormality of myocardial
ischemic mice. Moreover, 7,8-DHF reduced cell death, accompanied by inhibiting mitochondrial
superoxide anion generation [76]. Furthermore, exercise-induced BDNF confers certain aspects of its
cardioprotective effects through the activation of the BDNF/TrkB axis in a NO-dependent manner [77].
We found a lot more studies from recent years investigating the relation between BDNF and ROS
in ischemia. However, these studies are less relevant, because no causative relation was demonstrated
between BDNF and ROS. In all of these papers, the central nervous system or the neurons represented
the endpoints of the studies, and exclusively rodent animal models (rats and mice) were used
with a wide range of secondary end-points, i.e., oxidative stress [78–80], SOD [81–83], NOS [84,85],
HO-1 [86,87], or others [88–90].
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Table 4. Effect of different myokines on redox state in settings of I/R.
Myokine Species Organ/Cell Model Myokine Dose, Treatment Time,Route
Effect of Myokine on I/R
Injury Effect of Myokine on Redox State Ref.
BDNF
rat brainhippocampus ex vivo OGD 50 ng/mL after OGD cell death ↓
ROS ↓ (CellRox) *, NOX ↓, GPx ↓,
MDA+4-HNE ↓, TAC ↓, SOD-2 ↓ [72]
rat brain cortex ex vivo OGD 50 ng/mL after OGD cell death ↓




rat H9c2cardiomyoblasts in vitro H2O2
1 100 µM2 24 h before H2O2 cell death ↓ mitochondrial O2•− ↓ (MitoSox) * [76]
FSTL-1
mice adductor muscle hindlimbischemia
skeletal muscle-derived
transgenic FSTL-1
endothelial cell function ↑,
revascularization ↑ NOS-3 ↑ [91]
rat heart in vivo I/R 1 × 10
6 mesenchymal stem cells
injected into the abdomen under I/R
infarct size ↓, apoptosis ↓ MDA ↓, total SOD ↑ [92]
FGF-21 rat H9C2cardiomyoblasts in vitro H/R
0.25, 1 or 4 µg/mL during 6 h
reoxygenation cell death ↓, apoptosis ↓ O2
•−
↓ (DHE) * [93]
Decorin rat kidney in vivo I/R 100 µg/kg for 9 days afterreperfusion, ip. TGF-β1 ↓, apoptosis ↓ lipid peroxidation ↓, total SOD ↑ [94]
IGF-1 rat primarycardiomyocytes in vitro H/R 1 h pretreatment with 100 nM mitochondrial function ↑ MDA ↓ [95]
LIF
rabbit heart ex vivo I/R 5 × 10
7 U/mg, 24 h prior to heart
isolation, iv.
tension recovery ↑ protein carbonylation ↓, TBARS ↓,SOD-2 ↑ [96]
rat culturedoligodendrocytes in vitro OGD
cotreatment with 200 ng/mL LIF
during 24 h OGD LDH release ↓ Prdx4 ↑, total SOD ↓ [97]
rat brain in vivo I/R 125 µg/kg at 6, 24, and 48 hafter I/R, iv. N.A. SOD-3 ↑, total SOD ↑ [98]
rat primary corticalneurons in vitro OGD pretreatment with 200 ng/mL LDH release ↓ SOD-3 ↑ [98]
FGF-2 rat kidney in vivo I/R 500 µg/kg 30 min prior to I/R, ip. renal function ↑, apoptosis ↓, 3NT ↓, 8-OHdG ↓ [99]
1 H2O2 treatment to mimic I/R, 2 7,8-DHF a BDNF mimetic, BDNF: brain-derived neurotrophic factor, 3NT: 3-nitrotyrosine, 4-HNE: 4-hydroxynonenal, 7,8-DHF: 7,8-dihydroxyflavone,
8-OHdG: 8-hydroxy-2-deoxyguanosine, NOS-3: endothelial nitric oxide synthase, FGF-2: Fibroblast growth factor 2, FGF-21: Fibroblast growth factor-21, FSTL-1: Follistatin-like 1, GPx:
glutathione peroxidase, H/R: hypoxia/reoxygenation, IGF-1: Insulin-like growth factor 1, ip.: intraperitoneally, iv.: intravenously, LIF: leukemia inhibitory factor, MCAO: middle cerebral
artery occlusion, MDA: malondialdehyde, N.A.: not applicable, NOX: NADPH oxidase, O2•−: superoxide anion, OGD: oxygen-glucose deprivation, Prdx4: Peroxiredoxin-4, SOD:
superoxide dismutase, SOD-3: Extracellular superoxide dismutase [CuZn], TBARS: thiobarbituric acid reactive substances, ↑ and ↓indicate increase and decrease, respectively;↔ indicates
no changes; * indicates detection method.
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2.4. Follistatin-Like 1
Follistatin-like 1 (FSTL-1) is a TGF-β1 induced, secreted glycoprotein that belongs to the follistatin
family of proteins [100]. FSTL-1 is expressed and secreted by human skeletal muscle cells after
physical activity. Serum FSTL-1 level is increased after 60 min of cycling [101] and high-intensity
all-out sprint interval training [102], while 11 weeks of strength training enhanced FSTL-1 mRNA
expression in vastus lateralis and trapezius muscles [103]. Several articles reported the possible
involvement of FSTL-1 against ischemic diseases [104–106]. Resistance exercise-stimulated skeletal
muscle-derived FSTL-1 not only reached the heart via the circulation but also reverted post-AMI
cardiac remodeling and improved cardiac angiogenesis [107,108]. Both intravenous administration and
transgenic overexpression of FSTL-1 protein protected cardiomyocytes against I/R injury through the
Akt/AMPK pathway with subsequent NOS-3 activation and suppressed apoptosis and inflammatory
response [109,110]. However, some studies refer to FSTL-1 as a cardiokine rather than myokine,
appointing the heart as the major source of circulating FSTL-1 protein since its secretion is increasing
rapidly after myocardial injury [111,112]. Correspondingly, FSTL-1 derived from mesenchymal stem
cells protected against I/R in vivo and in vitro, enhanced SOD activity, and decreased malondialdehyde
concentration (Table 4) [92]. Furthermore, cardiac overexpression of FSTL-1 reduced the severity of
doxorubicin-induced cardiocytotoxicity via restoring the decreased protein level of nuclear factor
erythroid 2–related factor-2 (NRF-2), upregulating SOD-1 and SOD-2 mRNA expression and reducing
myocardial ROS, malondialdehyde, and 4-hydroxynonenal levels [113]. Additionally, it was reported
that circulating FSTL-1 in healthy individuals is positively correlated with derivatives of reactive
oxidative metabolites [114], suggesting that FSTL-1 could be induced by oxidative stress. Regarding
skeletal muscle, FSTL-1 promotes endothelial cell function and improves revascularization in ischemic
hindlimbs through activation of Akt-NOS-3 signaling (Table 4) [91]. Moreover, treatment of C2C12
murine skeletal muscle cell line with inflammatory cytokines, such as interferon-γ and IL-1β enhanced
FSTL-1 secretion [101].
2.5. Fibroblast Growth Factor-21
Fibroblast growth factor-21 (FGF-21) is a regulator of glucose and lipid metabolism [115] and
expressed mainly in the liver [116]. Apart from its pivotal role in energy balance, FGF-21 is also
synthesized [117] and even secreted by skeletal muscle after a single boost [118] and two weeks
of treadmill exercise [119]. A series of studies suggested that FGF-21 exhibits diverse beneficial
functions against myocardial infarction and adverse cardiac remodeling, while elevated circulating
FGF-21 is also suggested to be a sensitive biomarker for the detection of I/R injury during liver
transplantation [120], implying that elevation of blood FGF-21 might be considered as an endogenous
adaptive response against cellular damage. Treatment of cultured cardiomyocytes and adult mice with
the pro-inflammatory agent lipopolysaccharide enhanced cardiac FGF-21 protein levels resulting in
upregulated expression of antioxidant genes including SOD-2 and UCP-3, as well as decreased the
extent of ROS formation possibly via an autocrine manner [121]. On the other hand, FGF-21 also confers
cardioprotection via an endocrine manner. Skeletal muscle-derived FGF-21 improved cardiac function
reduced apoptosis and proinflammatory cytokines after myocardial infarction [122]. Furthermore,
serum FGF-21 concentration is elevated after myocardial infarction. However, the major source
of circulating FGF-21 is considered to be the liver and the adipose tissue [123,124]. The action of
Sirtuin 1 deacetylase, which is responsible for antioxidant gene expression in cardiac tissue [125–127],
is partially mediated by FGF-21 [121]. In line with that, in response to doxorubicin-induced oxidative
stress, FGF-21 pretreatment increased the amount of cardiac Sirtuin-1, thereby preventing subsequent
cellular injury [128]. The same study also revealed that pretreatment with FGF-21 suppressed
chronic doxorubicin-induced 3-nitrotyrosine, 4-hydroxy-2-nonenal, and MDA levels in murine hearts.
Intraperitoneal administration of recombinant human FGF-21 for 28 days enhanced both mRNA and
protein levels of SOD-2 and catalase, moreover mitigated angiotensin II-induced ROS release in the
murine heart [129]. Several studies implied that NRF-2 activation is essential for FGF-21 mediated
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antioxidant response. NRF-2 induced hepatic FGF-21 expression and secretion in obese mice [130]
and even protected the liver against oxidative stress [131], while FGF-21 deficiency enhanced type 1
diabetes-induced oxidative stress in the heart [132]. Furthermore, FGF-21 supplementation prevented
lipid- or diabetes-induced cardiac apoptosis and lipotoxicity-induced cardiomyopathy, possibly
through inhibition of Fyn-mediated export of NRF-2 from the nucleus [133,134]. In line with that,
fenofibrate treatment significantly ameliorated diabetes-induced renal oxidative stress and dysfunction,
and this beneficial effect is associated with increased FGF-21 expression and subsequent activation of
NRF-2 [135]. Additionally, FGF-21 treatment restored doxorubicin-induced downregulation of NRF-2,
as well as its target proteins, such as NADPH quinone oxidoreductase-1, catalase, and HO-1 levels [128].
Moreover, in vitro treatment of H9C2 cardiac cell line with FGF-21 protected against H2O2-induced
cell death and decreased superoxide anion formation after simulated I/R (Table 4) [93]. The proposed
mechanisms for the observed cytoprotective effect might be the enhancement of autophagy and
inhibition of angiopoietin-2 [136–138]. Another possible way of the suppression of oxidative stress
induced damage is the modulation of endoplasmic reticulum (ER) stress. FGF-21 expression and
secretion are increased in response to ER-stress while FGF-21 overexpression protected cardiomyocytes
against ER stress [139]. Additionally, FGF-21 transcription is highly regulated by activating transcription
factor 4 (ATF-4) and CCAAT enhancer-binding protein homologous protein (CHOP), two important
regulators of redox homeostasis and ER-stress [140].
2.6. Decorin
The small leucine-rich proteoglycan decorin is part of the extracellular matrix and a positive
regulator of muscle hypertrophy [141]. Secreted from myotubes during differentiation [142],
long term, combined endurance and resistance exercise upregulated decorin mRNA in vastus lateralis
muscles, also markedly elevated plasma decorin level immediately after a single boost of resistance
training [141]. Beyond that, decorin may ameliorate I/R injury via reducing oxidative/nitrative
stress [143]. Intraperitoneal administration of decorin before 60 min ischemia attenuated lipid
peroxidation and enhanced SOD levels in the kidney (Table 4) [94]. Moreover, decorin treatment
protected cultured rat cardiomyocytes exposed to simulated I/R-induced cell death [144]. In line with
that, decorin conferred antioxidant properties against traumatic brain injury [145], as well as attenuated
diabetes-induced cardiomyopathy and promoted angiogenesis, possibly through activating the IGF-1
receptor [146].
2.7. Myonectin
The recently identified myokine C1q and tumor necrosis factor-related protein 5, also known
as myonectin, is predominantly expressed by skeletal muscle and may function as an endocrine
factor [147]. Serum myonectin was increased after 8 weeks of aerobic exercise [148], while treadmill
running for 4 weeks enhanced myonectin mRNA and protein content in the soleus muscle and elevated
plasma myonectin level as well [149]. However, little is known about the potential modulatory effect of
myonectin on I/R related oxidative damage. B6 vitamin supplementation upregulated myonectin and
leukemia inhibitory factor, as well as NRF-2 mRNA expression in the gastrocnemius muscle, suggesting
a potential role of myonectin in the antioxidant system [150]. Moreover, systemic administration,
transgenic overexpression, and treatment of cultured myocytes with myonectin protected against
ischemic injury via decreasing the rate of apoptosis and inflammation [149].
2.8. Insulin-Like Growth Factor-1 (IGF-1)
Insulin-like growth factor 1 (IGF-1) is synthesized mainly in the liver and acts as a growth and
differentiation factor. IGF-1 is also synthesized by skeletal muscle after physical activity [151–154].
Apart from its prominent role in muscle hypertrophy and regeneration, IGF-1 exerts protection
against oxidative stress-induced cellular injury. The dominant isoform of muscle IGF-1 minimized
oxidative damage in senescent muscle via upregulating peroxisome proliferator-activated receptor
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gamma coactivator 1-alpha (PGC-1α), NRF-2, and Sirtuin-1 [155]. IGF-1 pretreatment of cultured
rat cardiomyocytes mitigated hypoxia/reoxygenation-induced cell death, reduced subsequent
oxidative stress, and inhibited MDA production (Table 4) [95]. IGF-1 overexpression suppressed
the formation of H2O2, hydroxyl radical, and nitrotyrosine accumulation, thus protected against
diabetic cardiomyopathy [156]. Likewise, attenuation of circulating IGF-1 levels, through knockout of
liver-specific IGF-1, resulted in downregulated expression of NRF-2 and its downstream targets NADPH
quinone oxidoreductase-1, γ-glutamylcysteine ligase, and HO-1 in the aorta [157]. Additionally,
the same research group assessed that exposing cultured aorta segments from IGF-1 deficient mice
to H2O2 or oxidized low-density lipoprotein exacerbated oxidative stress-mediated cellular injury.
Controversially, isolated cardiomyocytes from hepatic IGF-1 deficient mice showed decreased ROS
formation after treatment with the pro-oxidant paraquat [158]. Apart from its antioxidant properties,
IGF-1 protects against I/R injury both in vivo and in vitro. Intravenous injection of IGF-1 30 min
before left anterior descending artery ligation ameliorated myocardial infarct size and apoptosis [159].
Downregulation of IGF-1 during I/R through microRNA-320 and microRNA-489 aggravated the extent
of myocardial infarction, ventricular remodeling, and apoptotic cell death [160,161], proposing an
important IGF-1 mediated endogenous protection against ischemic cell death. This is further affirmed
by the findings that genetic depletion of mouse mast cell protease 4—presumably responsible for
endogenous IGF-1 degradation—alleviated myocardial infarct size, post-ischemic cardiac dysfunction
and remodeling [162]. IGF-1 also confers cardioprotection in ex vivo perfused myocardium [163]
since both supplementation of IGF-1 into the perfusion fluid or IGF-1 overexpression suppressed
I/R injury [164,165]. Recently it was demonstrated that subcutaneous IGF-1 supplementation for
3 days improved cardiac function after myocardial infarction [166]. Transgenic overexpression of
locally acting IGF-1 isoform (mIGF-1) mitigated paraquat-induced oxidative stress, alleviated cardiac
MDA production, ROS levels, as well as 4-hydroxy-2-nonenal and MDA protein adducts [127,167].
The proposed mechanism may involve the activation of Sirtuin-1 deacetylase since overexpression
of mIGF-1 isoform increased cardiac Sirtuin-1 protein level in both HL-1 cells and murine primary
cardiomyocytes, while genetic depletion of Sirtuin-1 abolished the protection induced by mIGF-1
against paraquat-induced oxidative damage.
2.9. Leukemia Inhibitory Factor (LIF)
LIF belongs to the IL-6 cytokine superfamily, presumed as a pleiotropic cytokine with a wide range of
activities, including modulation of cell proliferation and growth, bone formation, and neuronal protection.
LIF mRNA expression is acutely induced after 6 h of concentric exercise in the vastus lateralis [168], thereby
pointing to the skeletal muscle as a putative source of circulating LIF. Intravenous administration of
LIF protected rabbit hearts against ex vivo I/R injury, moreover increased myocardial SOD-2 activity,
decreased lipid oxidation, and protein carbonylation (Table 4) [96]. Additionally, LIF transfection
improved cardiac recovery and enhanced the proliferation of cardiomyocytes following myocardial
infarction [169]. LIF treatment mitigated middle cerebral artery occlusion [170] and focal cerebral
ischemia-induced injury, in the latter via upregulating the antioxidant enzyme peroxiredoxin 4 mRNA
in cultured oligodendrocytes and SOD-3 mRNA expression in cortical neurons (Table 4) [97,98]. LIF also
protected PC-12 cells against Antimycin A-induced oxidative damage, reduced ROS level, and restored
SOD activity [171]. Furthermore, LIF attenuated glucose-induced ROS production in podocytes,
decreased NADPH oxidase generation while enhancing total SOD levels [172].
2.10. Fibroblast Growth Factor 2 (FGF-2)
FGF-2, also known as basic fibroblast growth factor, is a pleiotropic protein with important roles
in angiogenesis, bone formation, cell differentiation, and migration. Despite lacking the secretion
signal, the low molecular weight isoform of FGF-2 is a secreted protein [173,174]. Cultured myocytes
exposed to in vitro mechanical stress or scratching responded with increased FGF-2 secretion in the
surrounding media [175–177], proposing that FGF-2 might be an exercise-induced myokine [178].
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Presumed to act via autocrine/paracrine manner, FGF-2 is well documented to protect against I/R.
However, it remains controversial whether the skeletal muscle-derived secreted FGF-2 isoform is
involved in cardioprotection. Cardiac-specific overexpression of FGF-2 conferred cardioprotection in
the ex vivo perfused murine heart [179–182], while FGF-2 knockout failed to attenuate the extent of I/R
injury [183]. Interestingly, it is proposed that the low molecular weight isoform of FGF-2 might have a
prominent role in these beneficial effects on the myocardium [184,185]. Additionally, treatment with
both low and high molecular weight isoforms of FGF-2 protected cultured rat cardiomyocytes against
doxorubicin-mediated oxidative stress [186], possibly via preventing the doxorubicin-induced decrease
in NRF-2 and enhancing the subsequent upregulation of HO-1 [187,188]. Intraperitoneal administration
of FGF-2 markedly alleviated I/R-induced kidney damage (Table 4) [99,189]. The proposed mechanism
of action might involve the attenuation of mitochondrial DNA damage as reflected by lowering the
amounts of 3-nitrotyrosine and 8-hydroxy-2-deoxyguanosine generation of tubular cells in ischemic
kidneys and inhibition of excessive ER-stress. FGF-2 is also involved in the protection against
cerebral ischemia [190] and mitigated H2O2-induced oxidative damage of PC-12 cells, possibly through
mediating ER-stress response [191].
2.11. Other Myokines
In the case of 8 other myokines, i.e., cathepsin B, follistatin, IL-7, IL-15, meteorin-like, musclin,
myostatin, and osteoglycin, no relevant literature was found in the context of ROS and I/R (Table 1,
Figure 1). However, their potential redox modulatory role is discussed in the next section.
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Figure 1. Modulation of ischemia/reperfusion-induced reactive oxygen species (ROS) formation and/or
elimination by myokines in different organs. This figure shows the groups of myokines affecting
ROS or antioxidant mechanisms in the heart, brain, liver, and kidneys, respectively, in the settings of
ischemia/reperf sion (thick l es). The effect of the i dividual myokines on specific molecular targets
are indicated with thin lines: T: negative effect, ↑: positive effect. BDNF: brain-derived neurotrophic
factor; FGF-2: fibroblast growth factor 2; FGF-21: fibroblast growth factor 21; FSTL-1: follistatin-like;
GPx: glutathione peroxidase; GSH: glutathione; HO-1: heme oxygenase-1; IGF-1: insulin-like growth
factor-1; IL-6: interleukin-6; IL-7: interleukin-7; IL-15: interleukin-15; LIF: leukemia inhibitory factor;
METRLN: meteorin-like; NOS: nitric oxide synthase; NOX: NADPH oxidase; ONOO−: peroxynitrite,
O2.−: superoxide anion, SOD: superoxide dismutase, ROS: reactive oxygen species. ?: no article was
found to support evidence between myokines and ROS. Figure 1 was created by the software Inkscape.
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3. Discussion
In summary, we found that several myokines confer protection against I/R injury in a variety of
organs. This protection often involves the modulation of ROS/RNS formation or elimination (Figure 1).
We may conclude that some myokines exert significant effects on the redox homeostasis of tissues.
Therefore, these mediators may potentially confer general protection against I/R injury. Irisin, IL-6,
and BDNF are the most powerful members of these myokines. One may speculate that the use of
these myokines in combination or application of physical exercise forms resulting in high irisin, IL-6,
and BDNF-release would provide an even more pronounced preventive or therapeutic effect against
ischemic stress. However, confirmation of these concepts needs to be done in future studies.
Importantly, all of the myokines that were investigated concerning ROS modulation were found to
(i) decrease ROS formation and its harmful consequences (e.g., lipid peroxidation, etc.), or (ii) increase
antioxidant enzymes protein level or activity. Superoxide anion was represented as the most frequent
target of redox status according to the studies we analyzed, and among the antioxidative defense
enzymes, SOD and GPx, were investigated most frequently. Taken together, the prooxidant effect of
myokines could hardly be found concerning I/R (Tables 2–4).
Although in our preliminary PubMed search, we found a relatively large number of myokines in
the context of I/R and ROS, it seems that only a portion of these myokines (9 out of 18) influences the
redox balance significantly and are in a causative relationship with ROS/RNS formation or elimination.
In several articles, the influence of myokines on ROS/RNS formation was only a secondary or tertiary
finding. Moreover, in the case of several other myokines (i.e., cathepsin, follistatin, IL-7, IL-15,
METRLN, musclin, myonectin, myostatin, osteoglycin), no or only very weak evidence was found to
link the individual myokines to possible modulation of redox balance (Figure 1). This does not exclude
the possibility that these myokines may be involved in the protection against I/R injury. However,
further studies are required to clarify their precise role and mechanism of action.
In recent years, exercise training and other forms of physical activity have become one of the
main clinical interventions for the prevention and treatment of (cardio)vascular diseases (sport as
medicine). Therefore, a better understanding of the mechanisms underlying myokine release holds
promise for the discovery of novel therapeutic targets and optimization of physical activity to improve
(cardio)vascular outcomes.
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